Viewing nowCombinationSeviwonjeong 10/40 mg
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.

MFDS item code 201404731 · Approved 2014.10.15 · Insurance code 657805410
Treatment of essential hypertension not controlled with monotherapy
This medication effectively lowers and controls blood pressure in patients with essential hypertension who have difficulty managing blood pressure with monotherapy of either Amlodipine or Olmesartan Medoxomil. This helps maintain stable blood pressure and contributes to the prevention of cardiovascular complications. It is used to assist patients in managing their blood pressure to maintain a healthy lifestyle.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time every day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using amlodipine 5 mg or olmesartan medoxomil 20 mg. - 10/20 mg: For patients whose blood pressure is not adequately controlled with monotherapy using olmesartan medoxomil 20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients on dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not be administered this medicine under Precautions for Use.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Pediatrics: The safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used by patients allergic to any of the active ingredients or similar components, by pregnant or nursing women, by patients with severe liver impairment, aortic stenosis, obstructive biliary disease, patients undergoing renal dialysis, patients in shock, and certain diabetic patients. For patients with insufficient body fluids or electrolytes, low blood pressure may occur, so their condition should be monitored closely when starting this medication, and appropriate treatment should be received if low blood pressure occurs. Hypotension may result from sudden vasodilation, so it should be used cautiously in patients with aortic stenosis, severe obstructive coronary artery disease, or congestive heart failure. Patients with renal impairment may experience further deterioration of kidney function while taking this medication, so caution is necessary, as liver impairment also affects the metabolism of this medication. Side effects such as dizziness, headache, hypotension, edema, dyspepsia, skin rash, etc., may occur while taking this medication; if any unusual symptoms appear, the patient should consult a physician. Taking this medication during pregnancy may lead to severe issues such as renal dysfunction in the fetus, oligohydramnios, and malformations, so women who are pregnant or planning to become pregnant should consult a doctor. Nursing mothers should discontinue nursing or stop taking this medication, as it can be transmitted through breast milk and may affect the baby. It is recommended that this medication not be used in pediatric patients under 18 years of age, as its safety and efficacy have not been established. Elderly patients should start with a lower dose, as they may have decreased liver or kidney function, and their condition should be closely monitored. In cases of overdose, severe hypotension and symptoms due to vasodilation may occur, so immediate medical attention is necessary and cardiac and respiratory functions should be closely monitored. This medication should be stored in a closed container to protect it from air and moisture and should be kept at a temperature between 1 and 30 degrees Celsius. Therefore, avoid hot or cold places and keep it in a cool, dry place. Interactions may occur when this medication is taken with other drugs, so patients should inform their doctor or pharmacist of any other medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a closed container to protect it from air and moisture, and it should be kept at a safe temperature between 1 and 30 degrees Celsius. Therefore, it is advisable to avoid very hot or very cold places and to keep it in a cool and dry location.
Reddish-brown round film-coated tablet
30 tablets (10 tablets/PTP x 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hana Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.